Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM (I5T-MC-AACY)
jRCT2031260319Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) and Cerebral amyloidosis comparing Donanemab with Placebo (2 arms). Primary endpoint: Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB). Started Aug 2026; status: recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)Cerebral amyloidosis
Beyond the preview
Go deeper on jRCT2031260319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260319.